Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 1 , Pages 17-24 , January 2009

Prevalence and association with diabetes and obesity of lipid phenotypes among the hypertensive Chinese rural adults

  • Xingang Zhang, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Zhaoqing Sun, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Dayi Zhang, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, General Hospital of Coal Mining Industry Group Fuxin, Shanghai, PR China
    • ,
  • Liqiang Zheng, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Jue Li, MD

      Affiliations

    • Heart, Lung and Blood Vessel Center, Tongji University, Shanghai, PR China
    • ,
  • Shuangshuang Liu, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Changlu Xu, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Jiajin Li, MD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • ,
  • Dayi Hu, MD

      Affiliations

    • Heart, Lung and Blood Vessel Center, Tongji University, Shanghai, PR China
    • ,
  • Yingxian Sun, MD, PhD

      Affiliations

    • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, PR China
    • Corresponding Author InformationCorresponding author: Yingxian Sun, MD, PhD, Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110004, PR China

References 

  1. World Health Organization. World Health Statistics Annual. Geneva, Switzerland: World Health Organization; 1996;
  2. Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, I: morbidity and mortality monitoring. Circulation. 2001;103:462–468
  3. Fager G, Wiklung O. Cholesterol reduction and clinical benefit (Are there limits to our expectations?). Arterioscler Thromb Vasc Biol. 1997;17:3527–3533
  4. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211–4218
  5. People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China (Baseline report from the P.R.C.-U.S.A. Collaborative Study). Circulation. 1992;85:1083–1096
  6. He J, Gu D, Reynolds K, et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation. 2004;110:405–411
  7. Sun Z, Zheng L, Wei Y, et al. The prevalence of prehypertension and hypertension among rural adults in Liaoning province of China. Clin Cardiol. 2007;30:183–187
  8. Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation. 2005;112:658–665
  9. Eriksson H, Welin L, Wilhelmsen L, et al. Metabolic disturbances in hypertension: results from the population study ‘men born in 1913’. J Intern Med. 1992;232:389–395
  10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  11. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease (Prevention of coronary heart disease. Scientific background and new clinical guidelines). Nutr Metab Cardiovasc Dis. 1992;2:113–156
  12. Wu Z, Yao C, Zhao D, et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China: results of Sino-MONICA project. Eur J Cardiovasc Prev Rehabil. 2004;11:275–283
  13. Gupta R, Gupta HP, Kumar N, et al. Lipoprotein lipids and the prevalence of hyperlipidaemia in rural India. J Cardiovasc Risk. 1994;1:179–184
  14. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care. 1991;14:195–202
  15. Shieh S-M, Shen M-DM, Fuh M-MT, et al. Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension. Atherosclerosis. 1987;67:49–55
  16. Ibrahim MM, Appel LJ, Rizk HH, et al. Cardiovascular risk factors in normotensive and hypertensive Egyptians. J Hypertens. 2001;19:1933–1940
  17. Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42:1298–1307
  18. Fong PC, Tam SC, Tai YT, et al. Serum lipid and apolipoprotein distributions in Hong Kong Chinese. J Epidemiol Community Health. 1994;48:355–359
  19. Pang RW, Tam S, Janus ED, et al. Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment. Atherosclerosis. 2006;184:438–445
  20. Pasquali R, Casimirri F, Pascal G, et al. Influence of menopause on blood cholesterol levels in women: the role of body composition, fat distribution and hormonal milieu (Virgilio Menopause Health Group). J Intern Med. 1997;241:195–203
  21. O'Brien T, Nguyen TT. Lipids and lipoproteins in women. Mayo Clin Proc. 1997;72:235–244
  22. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol. 1998;81(4A):47B–51B
  23. Cohen HW, Hailpern SM, Alderman MH. Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension. 2004;43:983–987
  24. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  25. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA. 1998;279:1615–1622
  26. Hoogwerf BJ, Waness A, Cressman M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft trial. Diabetes. 1999;48:1289–1294
  27. Grundy SM, Mok HYI, Zech L, et al. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest. 1979;63:1274–1283
  28. Garrison RJ, Wilson PW, Castelli WP, et al. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism. 1980;29:1053–1060
  29. Denke MA, Sempos CT, Grundy SM. Excess body weight: an under-recognized contributor to dyslipidemia in white American women. Arch Intern Med. 1994;154:401–410
  30. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet with or without exercise, in overweight men and women. N Engl J Med. 1991;325:461–466
  31. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–328
  32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2496
  33. Schonfeld G, Aguilar-Salina C, Elias N. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) in familial combined hyperlipidemia. Am J Cardiol. 1998;81(4A):43B–46B
  34. Betteridge DJ, Khan M. Review of the guidelines for management of dyslipidemia. Baillieres Clin Endocrinol Metab. 1995;9:867–890

 Supported by grants from the key technology Research and Development program of Liaoning Province (2003225003).

PII: S0147-9563(08)00023-X

doi: 10.1016/j.hrtlng.2008.02.001

Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 1 , Pages 17-24 , January 2009

Article Tools